Journal of Intelligent Systems and Internet of Things
  JISIoT
  2690-6791
  2769-786X
  
   10.54216/JISIoT
   https://www.americaspg.com/journals/show/3774
  
 
 
  
   2019
  
  
   2019
  
 
 
  
   A deep learning-driven multi-layer digital twin framework with miot for precision oncology in cancer diagnosis
  
  
   Division of AIML, Karunya Institute of Technology and Sciences, Coimbatore, India
   
    Venkatesan
    Venkatesan
   
   Department of Artificial Intelligence and Data Science, Panimalar Engineering College, Chennai, India
   
    E.
    Bhuvaneswari
   
   Division of CSE, Karunya Institute of Technology and Sciences, Coimbatore, India
   
    Venkatesan.
    R.
   
  
  
   This study introduces a novel deep learning-driven multi-layer digital twin framework, underpinned by the Model-Integration-Optimization-Testing (MIOT) methodology, to advance precision oncology in cancer diagnosis. The innovation lies in integrating multi-layered data, including molecular, clinical, and imaging modalities, into a patient-specific digital twin ecosystem. By combining deep learning with the MIOT framework, the proposed approach enables dynamic and predictive modelling tailored to individual patient profiles, facilitating simulations of tumor progression, diagnostic insights, and personalized treatment optimization. Pre-processing pipelines standardize the heterogeneous data, while convolutional and Recurrent Neural Networks        (RNN) extract high-level features from imaging and sequential data, respectively. The MIOT framework ensures a systematic design process: deep learning architectures like U-Net, DenseNet, and transformers are employed for tasks such as tumor segmentation, classification, and survival prediction. Data integration pipelines connect the digital twin seamlessly with clinical diagnostic tools to ensure interoperability. Multi-objective optimization algorithms, including evolutionary strategies and reinforcement learning, guide the digital twin in recommending personalized diagnostic and therapeutic pathways. State-of-the-art performance is demonstrated by rigorous validation on benchmark datasets, which yielded 96.3% diagnosis accuracy, 94.8% sensitivity, and 95.6% specificity across many tumor subtypes.
  
  
   2025
  
  
   2025
  
  
   16
   26
  
  
   10.54216/JISIoT.170102
   https://www.americaspg.com/articleinfo/18/show/3774